Analysis of various biomarkers in DIC patients with hypercytokinemia after hematopoietic stem cell transplantatio
Not Applicable
Recruiting
- Conditions
- Stem cell transplantation
- Registration Number
- JPRN-UMIN000007394
- Lead Sponsor
- First Department of Internal Medicine,Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Decision of ineligibility by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link hypercytokinemia to DIC in post-hematopoietic stem cell transplantation patients?
Are there specific biomarkers that correlate with hypercytokinemia severity in hematopoietic stem cell transplantation-induced DIC?
How does the therapeutic approach in JPRN-UMIN000007394 compare to standard-of-care for managing post-transplant DIC and hypercytokinemia?
What adverse events are associated with biomarker-guided interventions for hypercytokinemia in hematopoietic stem cell transplantation patients?
Are there combination therapies or alternative molecular targets being explored for treating hypercytokinemia-induced DIC following hematopoietic stem cell transplantation?